

18.01.2021

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,


SUB:PRESS RELEASE -DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015.

Please find the enclosed copy of Press Release being published today.

Kindly take the same on your records.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosure: As above



Press Release

For immediate release

CAPLIN STERILES ENTERS INTO A STRATEGIC PARTNERSHIP WITH JAMP PHARMA GROUP FOR CANADA

- Agreement includes six injectable products to be filed for Health Canada approval through JAMP Pharma GROUP

Chennai, Jan 18, 2021: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) announced that Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a strategic partnership with JAMP Pharma Group for six injectable products to be filed shortly in Canada. Some of these products have already been filed by Caplin Steriles in the USA.

Commenting on the transaction, Mr C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited, said: *"We have targeted Canada as one of our key expansion areas in Regulated Markets and we are excited to work with JAMP, one of the fastest growing companies in Canada. We are confident that we will be adding more products to this partnership in due course."*

Louis Pilon, JAMP Pharma Group's CEO added *"We are very pleased and excited to enter into this partnership with Caplin Point Laboratories Limited. This partnership will allow us to continue our mission to provide more affordable options to Canadian patients, as well as our retail and institutional partners. We certainly hope to collaborate on more products with our new partner in the coming years."*

ABOUT CAPLIN STERILES LTD

Caplin Steriles Ltd, a Subsidiary of Caplin Point Laboratories Limited, is a niche sterile product manufacturing company that is approved by US FDA and EU-GMP. The company has filed 19 abbreviated new drug applications (ANDAs) so far in the US, and currently holds 11 FDA approvals. The company has a larger pipeline of 35+ ANDAs that it intends to file over the next 4 years.

ABOUT CAPLIN POINT LABORATORIES LTD

Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model, catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that produce a complete range of finished dosage forms. The Company has also entered regulated markets such as the US through its subsidiary, Caplin Steriles Limited.

Caplin Point has been selected on Forbes Asia's "200 Best under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

ABOUT JAMP PHARMA GROUP

JAMP Pharma Group is a privately-owned Canadian pharmaceutical company with its head office in the greater Montreal area. Experiencing a sustained phenomenal growth for more than 10 years, JAMP Pharma Group has a portfolio of 270+ molecules, including injectables, oncology, multiple-sclerosis, HIV and ophthalmic products. JAMP GROUP is a leader in product launches in the pharmaceutical industry in Canada. The company is also growing through a diversified portfolio of biosimilars, branded Orimed Pharma prescription products as well as vitamins, supplements and natural health products from Wampole and Laboratoire Suisse.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Caplin Mr. Vinod Kumar (Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net Mr. Rahul Thakur Ernst & Young LLP, Rahul.thakur@in.ey.com	Registered Office 3 rd Floor, Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel : +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: www.caplinpoint.net
--	---